ConductScience.org, home

Paper36912406

Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.

Ediger D and 3 others. Tuberk Toraks, 2023. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab. Papers, record 36912406. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36912406

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.
PubMed
Journal
Tuberk Toraks
PubMed
Year
2023
PubMed
Publication types
Observational Study, Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.91
iCite
Revised in PubMed
2024-03-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ediger DDane
2Günaydın FEFatma Esra
3Erbay MMüge
4Pekbak GGülseren

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Asthmatic AgentsMajor topic
AsthmaMajor topic
Adult
Humans
Omalizumab
Retrospective Studies
Antibodies, Monoclonal, Humanized
Treatment Outcome
Adrenal Cortex Hormones

Source PubMed

Download CSV of topics

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128859150The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.PLoS One2017https://conductscience.org/library/papers/28859150PubMed
223350994Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.J Asthma2013https://conductscience.org/library/papers/23350994PubMed
38912771IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity.Am J Respir Crit Care Med1996https://conductscience.org/library/papers/8912771PubMed
419846286Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.Respir Med2010https://conductscience.org/library/papers/19846286PubMed
515733511Phenotypes of asthma revisited upon the presence of atopy.Respir Med2005https://conductscience.org/library/papers/15733511PubMed
628800272Omalizumab in non-allergic Asthma: A report of 13 cases.J Asthma2018https://conductscience.org/library/papers/28800272PubMed
726747278Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.BMC Pulm Med2016https://conductscience.org/library/papers/26747278PubMed
833220106Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment.Allergy2021https://conductscience.org/library/papers/33220106PubMed
9766679Immediate skin-test reactivity in a general population sample.Ann Intern Med1976https://conductscience.org/library/papers/766679PubMed
1027824606Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.Eur Respir J2016https://conductscience.org/library/papers/27824606PubMed
1129545284Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.Eur Respir J2018https://conductscience.org/library/papers/29545284PubMed
129689343
Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults.
Allergy1998https://conductscience.org/library/papers/9689343PubMed
1322525394Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.Allergy Asthma Proc2012https://conductscience.org/library/papers/22525394PubMed
1430322442Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients.Turk Thorac J2018https://conductscience.org/library/papers/30322442PubMed
1512100301Allergic vs nonallergic asthma: what makes the difference?Allergy2002https://conductscience.org/library/papers/12100301PubMed
1627507234Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).BMJ Open2016https://conductscience.org/library/papers/27507234PubMed
1723709757Against all odds: anti-IgE for intrinsic asthma?Thorax2014https://conductscience.org/library/papers/23709757PubMed
1823579324A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.Chest2013https://conductscience.org/library/papers/23579324PubMed
1921702660Asthma-related comorbidities.Expert Rev Respir Med2011https://conductscience.org/library/papers/21702660PubMed
2028822787
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet Respir Med2017https://conductscience.org/library/papers/28822787PubMed

See all 21 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
41790360Emerging Therapeutic Strategies in Asthma: Advances in Treatment, Drug Delivery, Drug Adherence, and Disease Management.Curr Allergy Asthma Rep2026https://conductscience.org/library/papers/41790360PubMed
40933990New insights into mesenchymal stem cells in inflammatory subtypes of asthma.Front Immunol2025https://conductscience.org/library/papers/40933990PubMed
40329860Obesity: Next game changer of allergic airway diseases?Clin Transl Med2025https://conductscience.org/library/papers/40329860PubMed
38878250Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.Curr Allergy Asthma Rep2024https://conductscience.org/library/papers/38878250PubMed
38812719Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma.Front Allergy2024https://conductscience.org/library/papers/38812719PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IGHE3497PubTator's text mininghttps://conductscience.org/library/genes/3497

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36912406

GET https://conductscience.org/api/papers/v1/36912406/references?page=2